EU Still Resisting COVID-19 Vaccine IP Waiver
EFPIA 'Deeply Concerned' About Compulsory Licensing Proposal
The pharmaceutical industry and Médecins Sans Frontières have both criticized the EU’s proposals for avoiding a waiver of intellectual property rights on COVID-19 vaccines and treatments, albeit for different reasons.
You may also be interested in...
Expectations will be high after the COVID-19 product IP waiver plan took a big step forward and G7 leaders prepare for discussions on the global recovery from coronavirus, tackling climate change and other weighty subjects.
Biolyse is seeking a compulsory license for J&J’s COVID-19 vaccine but achieving its goal is proving to be far from easy. The Canadian company argues that its experience illustrates the need for a change in approach to intellectual property rights at a local and global level.
Coronavirus Notebook: EMA To Decide On Comirnaty In 12-15-Year-Olds, Cuba Presses On With Homegrown Vaccine Rollout
At global level, Médecins Sans Frontières has called for all countries to support a revised version of the IP waiver for COVID-19 vaccines, singling out the recalcitrant European Commission for special attention.